We therefore evaluated whether FLLL32 would affect the responsiveness of PBMCs to stimulation with clinically relevant cytokines that mediate tumor progression (IL 6), immunosurveillance (IFN-γ) or T and NK cell survival (IL 2) [34-36]. Here, IFNG is linked to neoplasm.